Atıf İçin Kopyala
Ancin B., Ozercan M. M., Yilmaz Y., UYSAL S., KUMBASAR U., SARIBAŞ Z., ...Daha Fazla
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.4, ss.1050-1057, 2022 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
52
Sayı:
4
-
Basım Tarihi:
2022
-
Doi Numarası:
10.55730/1300-0144.5407
-
Dergi Adı:
TURKISH JOURNAL OF MEDICAL SCIENCES
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.1050-1057
-
Anahtar Kelimeler:
Nonsmall cell lung cancer (NSCLC), soluble programmed cell death protein 1 (sPD-1), soluble programmed cell death ligand 1 (sPD-L1), thoracic surgery, PD-L1, PLASMA, EXPRESSION, BLOCKADE, THERAPY
-
Hacettepe Üniversitesi Adresli:
Evet
Özet
Background/aim: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact with programmed cell death protein 1 (PD-1), causing immunosuppression. The aim of our study is to examine the correlation between the serum sPD-1 and sPD-L1 levels and clinicopathological characteristics in patients with nonsmall cell lung cancer. We also compared our results with the healthy population (control group).